Skip to main content

dabigatran etexilate (Pradaxa®)

 

Status: In progress

Treatment of VTE and prevention of recurrent VTE in paediatric patients from 8 years to less than 18 years of age.

 Draft Recommendation: dabigatran (Pradaxa) 2293 (PDF, 168Kb)

Medicine details

Medicine name dabigatran etexilate (Pradaxa®)
Formulation 75 mg, 110 mg, 150 mg hard capsules
Reference number 2293
Indication

As above

Company Boehringer Ingelheim Ltd
BNF chapter Cardiovascular system
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 08/12/2021
Date of issue TBC